anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Adverse reactions seen during continuous epidural clonidine infusion are dose-dependent and typical for a compound of this pharmacologic class. The adverse events most frequently reported in the pivotal controlled clinical trial of continuous epidural clonidine administration consisted of hypotension, postural hypotension, decreased heart rate, rebound hypertension, dry mouth, nausea, confusion, dizziness, somnolence, and fever. Hypotension is the adverse event that most frequently requires treatment. The hypotension is usually responsive to intravenous fluids and, if necessary, appropriate parenterally-administered pressor agents. Hypotension was observed more frequently in women and in lower weight patients, but no dose-related response was established.

Implantable epidural catheters are associated with a risk of catheter-related infections, including meningitis and/or epidural abscess. The risk depends on the clinical situation and the type of catheter used, but catheter related infections occur in 5% to 20% of patients, depending on the kind of catheter used, catheter placement technique, quality of catheter care, and length of catheter placement.

The inadvertent intrathecal administration of clonidine has not been associated with a significantly increased risk of adverse events, but there are inadequate safety and efficacy data to support the use of intrathecal clonidine.

Epidural clonidine was compared to placebo in a two week double-blind study of 85 terminal cancer patients with intractable pain receiving epidural morphine. The following adverse events were reported in two or more patients and may be related to administration of either clonidine hydrochloride or morphine.

An open label long-term extension of the above trial was performed. Thirty-two subjects received epidural clonidine and morphine for up to 94 weeks with a median dosing period of 10 weeks. The following adverse events (and percent incidence) were reported: hypotension/postural hypotension (47%); nausea (13%); anxiety/confusion (38%); somnolence (25%); urinary tract infection (22%); constipation, dyspnea, fever, infection (6% each); asthenia, hyperaesthesia, pain, skin ulcer, and vomiting (5% each). Eighteen percent of subjects discontinued this study as a result of catheter-related problems (infections, accidental dislodging, etc.), and one subject developed meningitis, possibly as a result of a catheter-related infection. In this study, rebound hypertension was not assessed, and ECG and laboratory data were not systematically sought.

The following adverse reactions have also been reported with the use of any dosage form of clonidine. In many cases patients were receiving concomitant medication and a causal relationship has not been established:
The purpose of this study is to explore an aerobic walking program on memory, subjective cognitive complaints, and brain-derived neurotrophic factor. In quantitative study with experimental design, qualified subjects will be randomly assigned to experimental or control group. Experimental subjects will perform six-month aerobic walking program and control group receive routine care. The outcome measurements included memory, subjective cognitive complaints, and brain-derived neurotrophic factor. Data will be collected at baseline, the end of the six-month intervention. Data will be analyzed using Generalized Estimation Equation evaluate the effect of the intervention program.
Ischemic Compression technique will be performed on the patients of group B after the diagnosis of trigger points in particular muscles by diagnostic ultrasound. The complete treatment session will be comprised of 3 sessions per week for two weeks followed by follow up after 1 month until the symptoms have been improved.
1,189,367. Cancerostatic substance from protozoa M. MATSUBARA. 23 Oct., 1967 [9 Nov., 1966], No. 48024/67. Heading A5B. A cancerostatic and cancer diagnosis substance is obtained by extracting unicellular protozoa of a species of Paramecia with water or an aqueous solvent, adding alcohol or acetone to the extract so formed to form a precipitate and dissolving the precipitate in water. The aqueous solvent may be aqueous acid or aqueous alkali of pH 2 to 8 or aqueous sodium chloride or acetate. The extract may be heated to 80 ‹C., cooled, the precipitate centrifuged and dissolved in distilled water, the solution heated to 93‹C and cooled, the precipitate dissolved in aqueous sodium chloride and the active material precipitated by the addition of alcohol. The species specified are Paramecium aurelia, P. bursaria, P. calkinsi, P. caudatum, P. multi-mieulonueleatum, P. polycaryum, P. trichium. P. woodruffi and Killer paramecium. The active material is a glycoprotein.
Patients will receive first dose of 90mg ticagrelor tablets (powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure, followed by 90mg of ticagrelor 12 hours after the first dose.Thereafter, the patients will take 90mg of ticagrelor orally bid, at approximately 12-hourly intervals. The total study period is 3 months.
The invention relates to cordyceps sinensis powder and application thereof and also relates to a preparation method of the cordyceps sinensis powder. The preparation method comprises the steps of coarse grinding, proportioning, nano grinding, vacuum freeze-drying and the like. In the invention, by adopting a dry-wet sub-step grinding method and taking water as a medium, the heat effect generated by friction can be reduced, and the active ingredients of cordyceps sinensis are effectively protected for sure. In the invention, the adenosine content, cordycepin content, polysaccharide content and mannitol content of the cordyceps sinensis powder are obviously higher than those of the cordyceps sinensis powder ground by a mechanical dry method, wherein the cordycepin content is particularly high. The method provided by the invention overcomes the shortcomings that the mixing is not uniform and the integrity of the active ingredients is damaged in the prior art. Through the method provided by the invention, the cordyceps sinensis is ground to 900-300nm to obtain uniform and stable nano particles. The method provided by the invention has the advantages of short flow, low equipment investment, excellent product, great application prospect and broad market prospect.
Esophageal cancer is one of the most common malignant tumors in China. In Asian countries, esophageal squamous carcinoma is the main pathological type of esophageal carcinoma. Prognosis of esophageal squamous carcinoma is usually poor and surgery is the only radical treatment. However, the optimal therapy pattern for local advanced esophageal carcinoma is still unclear. Part of the patients that clinical staging as T4 and with bulky lymph node metastasis are initially diagnosed as borderline-resectable, which means patients may be able to undergo R0 resection. However, for patients who are diagnosed as borderline-resectable esophageal carcinoma, there are still no sufficient studies implicate that how to improve R0 resection rate by convertion chemotherapy. Cisplatin in combination with 5-FU and docetaxel regimen(DCF) was reported as effective neoadjuvant chemotherapy in treating esophageal squamous carcinoma. However, studies also showed that the DCF regimen caused severe adverse reaction. The mechanism of paclitaxel is similar to docetaxel while with less adverse events than docetaxel. Based on the research situation mentioned above, the investigators decided to conduct a phase II clinical trial to further explore the efficacy and safety of paclitaxel in combination with cisplatin and 5-FU (TPF) induction chemotherapy for locally advanced borderline-resectable esophageal squamous carcinoma.
The invention discloses a traditional Chinese medicine composition used for treating epilepsy. The traditional Chinese medicine composition is prepared form 19 raw medicines of pinellia tuber (processed with alum), tangerine peel, capejasmine (stir-fried), chinese arborvilae seed, rhizoma arisaematis (prepared), raw dragon teeth, scorpion, bombyx batryticatus, nutgrass galingale rhizome, radix paeoniae alba, medicated leaven (stir-fried), cornu saigae tataricae, concretio silicea bambusae, poria cocos (schw.) wolf, orange fruit (stir-fried with bran), acorus calamus, asiatic plantain seed, rhizoma curcumae zedoariae, and raw oyster. The raw medicines are formulated with certain weight proportions (g). The traditional Chinese medicine composition is easy to prepare, and is convenient to use. With the composition, both principal and subordinate symptoms can be simultaneously treated. The traditional Chinese medicine composition is economic, and brings small side-effects.
INTRODUCTION: Cases of myocarditis after COVID-19 messenger RNA (mRNA) vaccines administration have been reported. Although the majority follow a mild course, fulminant presentations may occur. In these cases, cardiopulmonary support with venoarterial extracorporeal membrane oxygenation (V-A ECMO) may be needed.
RESULTS: We present two cases supported with V-A ECMO for refractory cardiogenic shock due to myocarditis secondary to a mRNA SARS-CoV2 vaccine. One of the cases was admitted for out-of-hospital cardiac arrest. In both, a peripheral V-A ECMO was implanted in the cath lab using the Seldinger technique. An intra-aortic balloon pump was needed in one case for left ventricle unloading. Support could be successfully withdrawn in a mean of five days. No major bleeding or thrombosis complications occurred. Whereas an endomyocardial biopsy was performed in both, a definite microscopic diagnosis just could be reached in one of them. Treatment was the same, using 1000mg of methylprednisolone/day for three days. A cardiac magnetic resonance was performed ten days after admission, showing a significant improvement of the left ventricular ejection fraction and diffuse oedema and subepicardial contrast intake in different segments. Both cases were discharged fully recovered, with CPC 1.
CONCLUSIONS: COVID-19 vaccine-associated fulminant myocarditis has a high morbidity and mortality but presents a high potential for recovery. V-A ECMO should be established in cases with refractory cardiogenic shock during the acute phase.
Oxaliplatin will be given as an intravenous infusion over 60 minutes on Days 1 and 14 at a dose of 100 mg/m2 for each cycle. Gemcitabine (1000 mg/m2) will be given on days 1 and 14 as an intravenous infusion over 30 minutes immediately prior to Oxaliplatin.
Subjects to be considered recreationally must regularly engage in \>150 min/wk of physical activity (e.g., resistance training, sport or activity specific exercise, group exercise, or aerobic exercise). Healthy participants, defined as not currently injured, or recovering from an injury within the past 12 months, or undergone surgery within the last 12 months, or with any known history of moderate to severe traumatic brain injury resulting in impaired judgment or inability to make sound decisions or mild traumatic brain injury (mTBI, also commonly named "concussion") within the last 12 months.
AXERT has been approved by the FDA for the treatment of migraine headache with or without aura in adults. Early treatment of a migraine headache, independent of headache pain intensity symptoms, may provide the optimal therapeutic response. This is a multi-center, open label study to test the efficacy (effectiveness) and tolerability of AXERT when treating a migraine at the onset of headache pain versus treating a migraine only after the headache pain has reached at least moderate intensity. Patients will self-administer 12.5 milligrams of AXERT for the treatment of 2 migraine headaches. Centers will be randomly assigned to 1 of 2 treatment interventions in which patients will sequentially treat both migraine headaches with 12.5 milligrams of AXERT using either the early treatment regimen (ET; ie, at the onset of pain) or conditional treatment regimen (CT; ie, after the headache has reached at least moderate intensity). Data will be collected regarding treatment response during and after each migraine headache. For each headache, patients will record study information and data during 3 telephone calls using Interactive Voice Response System (IVRS) technology. It is expected that patients who take 12.5 milligrams of AXERT at the first sign of pain of any intensity due to a migraine headache will experience an overall shorter duration of their migraine than patients who take AXERT 12.5 mg when their migraine pain has reached at least moderate pain intensity. In addition, it is expected that almotriptan malate (AXERT®) is generally well-tolerated.

AXERT 12.5 milligram tablet orally either at the onset of migraine pain (within 1 hour of the start of a migraine-ET regimen) or when migraine pain reaches at least moderate intensity (CT regimen).
PURPOSE:To provide the titled gene separated by a gene recombination DNA technique and useful for the microbial production of recombinant human cytochrome C. CONSTITUTION:A DNA sequence coding an amino acid sequence of human cytochrome C protein expressed by the formula (the underlined TTG may be TTA). A host cell (e.g. yeast) is transformed with a plasmid containing said DNA sequence and the obtained recombinant host cell is cultured. A recombinant human cytochrome C free from acetylated N-terminal is separated from the cultured bacterial cell and, as necessary, the N-terminal is acetylated to obtain a human cytochrome C useful as a tissue respiration activator. Said DNA sequence can be prepared by conventional process from the whole DNA prepared from a human tissue. As an alternative, it can be prepared by screening a human tissue-originated chromosome DNA library using a 3'-nondecoded region of human cytochrome C cDNA as a probe.
An improved method of porcelain dental restoration is provided which gives strong, aesthetically pleasing restorations in a wide variety of contexts such as inlays, onlays or overlays. The method involves first preparing a tooth requiring restoration by removing the decayed portions and exposing dentin surface, whereupon a lining material (e.g. a glass ionomer) is applied to the exposed dentin. An impression of the patient's teeth is next taken, whereupon a refractory positive impression of the prepared tooth is fabricated. Next, a porcelain restoration is produced by appropriate layering and firing to give a restoration piece which substantially conforms to the shape of the originally decayed portion of the tooth. Finally, the porcelain restoration is fused to the natural tooth by means of fusing cement system which mechanically and chemcially bonds to porcelain, lining cement and adjacent enamel surfaces. The resultant dental restoration produces a restored tooth having a strength approaching that of the original tooth.
Patients receive docetaxel IV over 60 minutes, ramucirumab IV over 60 minutes, and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Single arm of 6 patients undergoing subretinal injection of Gene Therapy using rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus. Each patient received the injection in one eye.
With this research the investigators hope to determine the lowest dose of ropivacaine used in transversus abdominis plane (TAP) blocks that can effectively treat pain in women after cesarean section (c-section). The TAP is a space between the muscle layers of the abdominal wall that houses nerves supplying the abdominal skin. The investigators will inject the local anesthetic ropivacaine into this space to freeze these nerves and prevent pain following c-section. The investigators will compare three different doses of ropivacaine (0.5%, 0.25%, 0%) to determine the lowest dose that controls pain with the fewest side effects. Participants in this study will receive 0.5% (Group 1), 0.25% (Group 2), or 0% (Group 3) ropivacaine TAP blocks to control pain after c-section. At 2, 6, 12, 24, and 48 hours after cesarean section visual analog pain scores (VAS) for pain on movement, pain at rest, and pain with cough will be collected along with the time to first postoperative analgesic request, patient satisfaction scores, and patient demographics. The analgesic regimen will be considered effective if it provides lower average visual analog scores for pain with movement. Secondary outcomes will be higher patient satisfaction, better pain control, fewer postoperative analgesic requests, and fewer side effects.
Couples in CBCT-OB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks in-person in the therapist's office.
<b>Background and Objective:</b> Non-Suicidal Self-Injury (NSSI) is a mental health threat that is a major concern among adolescents and young adults nowadays. It is assumed that NSSI is involved in the mesocortical dopamine reward system, the endogenous opioid system and the overstimulation of the stress system. This study aims to investigate the correlation between Opioid Receptor Kappa 1 (OPRK1) rs7016778 and rs7824175 gene polymorphisms, Kappa Opioid Receptor (KOR) and Dynorphin level with NSSI. <b>Materials and Methods:</b> This research was a cross-sectional comparative study between 84 subjects diagnosed with NSSI and 76 controls. The method used was purposive sampling. The NSSI was determined by using the NSSID and ISAS questionnaire according to DSM-5. The examination of polymorphism of the OPRK-I gene was examined using a Polymerase Chain Reaction (PCR) and the level of KOR and Dynorphin was determined using ELISA. <b>Results:</b> The OPRK1 rs7016778 gene polymorphism was more common in the NSSI group. The OPRK1 rs7824175 gene polymorphism was more common in the control group. The KOR and Dynorphin levels were higher in the NSSI group. There were differences in KOR levels between NSSI and the control group. There is a relationship between KOR levels and Dynorphin levels with NSSI. There were no differences in the OPRK1 gene polymorphisms rs7016778 and rs7824175 between NSSI subjects and controls. There was no difference in Dynorphin levels between NSSI subjects and controls. <b>Conclusion:</b> The role of the Kappa Opioid Receptor (KOR) and Dynorphin in the pathophysiology of NSSI can be considered.
POI women randomized to the 4-step ASCOT technique will receive a direct ovarian injection of G-CSF mobilized and activated PRP. For each patient, both ovaries will be directly injected with the G-CFS activated PRP (4-step ASCOT). Follow up (AFC, AMH, FSH and E2 determinations) will be developed for 6 months and COS initiated if growing antral follicles detected.
Objective: To determine the relationship between Q angle and quadriceps muscle activation on dynamic balance in women. Design: Correlational Study. Setting: University. Participants: Forth women will be included in the study. Interventions: Q angle in standing and supine positions, quadriceps muscle activation, static and dynamic balance and functionality were measured. Main Outcome Measurements: Q angle will measured with a tape measure; muscle activation will measured with Surface Electromyography (EMG) static balance will measured with Flamingo Balance Test (FBT); dynamic balance will measured with ProKin 252 Techno Body device; and, functionality will measured with Short Form Musculoskeletal Assessment (SFMA). Before the evaluation of EMG amplitude on dynamic balance position, the Q angle will measured in supine and standing positions. The EMG signals collected by measuring the muscle activation of the Vastus Medialis and Vastus Lateralis during dynamic balance position on the ProKin device will recorded.
The pharmacokinetics of clonidine is dose-proportional in the range of 100 to 600 mcg. The absolute bioavailability of clonidine on oral administration is 70% to 80%. Peak plasma clonidine levels are attained in approximately 1 to 3 hours.

Following intravenous administration, clonidine displays biphasic disposition with a distribution half- life of about 20 minutes and an elimination half-life ranging from 12 to 16 hours. The half-life increases up to 41 hours in patients with severe impairment of renal function. Clonidine crosses the placental barrier. It has been shown to cross the blood-brain barrier in rats.

Following oral administration about 40% to 60% of the absorbed dose is recovered in the urine as unchanged drug in 24 hours. About 50% of the absorbed dose is metabolized in the liver. Neither food nor the race of the patient influences the pharmacokinetics of clonidine.

The antihypertensive effect is reached at plasma concentrations between about 0.2 and 2.0 ng/mL in patients with normal excretory function. A further rise in the plasma levels will not enhance the antihypertensive effect.
AZT has been shown to delay the progression of AIDS in HIV infected individuals. However, bone marrow toxicity is a frequent adverse effect. Also, HIV resistance to AZT sometimes occurs in patients who initially respond to treatment, but later have progression of the disease. Thus, new drug treatments are needed. Studies of ddI in adults and children indicate some effectiveness of the drug. A direct comparison of AZT and ddI treatment in children has not been made. Combination antiviral treatment (AZT plus ddI) may give added therapeutic benefit to children.

Patients are placed by random selection into one of three groups to receive either AZT alone, ddI alone, or AZT and ddI. This is a double-blind study: neither patient nor treating physician knows which group patient is in. If patients are receiving either AZT or ddI alone and they develop drug toxicity (after dose reduction), or if HIV disease progresses, the alternative single drug is offered. If patients receiving both drugs develop drug toxicity (despite dose reduction) or if HIV disease progresses, they discontinue study drug and are offered the best alternative therapy. PER AMENDMENT 6/26/95: Initial monotherapy AZT arm is unblinded and no further crossover therapy for any arm is permitted. Patients who reach crossover criteria on initial blinded ddI or AZT+ddI will be unblinded and permanently discontinued from study drugs.
Mantle cell lymphoma is considered to have the worst outcome of all non-Hodgkins lymphomas. Since 1997, the Nordic Lymphoma Group has conducted phase II studies in order to improve the results for this lymphoma subtype. The first study included high-dose therapy with autologous stem cell support in the first line of treatment. The results showed the importance of a high quality response to pre-transplant induction treatment, and that CHOP-based regimen alone did not achieve this. Thus, the second trial was designed to improve remissions by including Rituximab and high-dose Ara-C. Results now show that a high rate of molecular remission in the bone marrow was achieved, and the 3-year FFS was improved in comparison to the first study (80% vs 24%). Furthermore, patient who had a molecular relapse (t(11;14) or IgV-gene) were treated with 4 doses of Rituximab and many converted back to be PCR negative.

The present and thus third phase II study aims to improve the high-dose regimen by adding Zevalin radioimmunotherapy in patients who are not in CR prior to transplant. Data from the last trial show that patients not in CR at this point have a worse outcome (3 year FFS of 63%, vs 85% for CR patients). Monitoring for molecular relapse in the bone marrow will be done, and patients who become PCR positive will be treated with Rituximab in order to evaluate the value of this strategy.